About Stimate.com

Stimate.com is an information resource for patients, families, and healthcare professionals seeking more information about von Willebrand disease, and is brought to you by CSL Behring.

CSL Behring is a global leader in the plasma protein biotherapeutics industry, dedicated to treating rare and serious diseases and improving the quality of life of patients throughout the world. As a company with a long history of creating a stable supply of life-saving therapies, CSL Behring (formerly ZLB Behring and Aventis Behring) provides plasma-derived and recombinant products that are used in the treatment of individuals with von Willebrand disease, hemophilia, and immune deficiency disorders as well as the treatment of cardiac surgery patients and burn victims.

CSL Behring has developed Stimate.com as part of our commitment to families affected by von Willebrand disease. To learn more about how CSL Behring is focused on providing innovative, safe, and quality therapies for the customers they serve, please visit www.CSLBehring-us.com.

CSL Behring's Marketing, Medical Affairs, Regulatory, Legal, and IS departments are responsible for the content and development of Stimate.com. The information provided on the site is designed to support, not replace, the information provided through the relationship that exists between you and your physician.

Stimate.com does not host or receive funding from advertising.

Important Safety Information

Stimate^® Nasal Spray is contraindicated in individuals with a known hypersensitivity to desmopressin or any of the components of Stimate^®. Stimate^® should not be used in patients with type 2B VWD, since platelet aggregation may be induced. Stimate^® Nasal Spray is for intranasal use only.

To decrease the potential for hyponatremia or water intoxication, especially in the young and the elderly, patients using desmopressin who are not in need of antidiuretic hormone for its antidiuretic effect should be cautioned to reduce fluid intake, ingesting only enough to satisfy thirst. Such patients should be monitored for the rare occurrence of an extreme decrease in plasma osmolality that could result in seizures, possibly leading to coma.

Other adverse reactions reported with use of injectable and/or intranasal desmopressin acetate include headache, nausea, somnolence, dizziness, chest pain, palpitations and tachycardia, and severe allergic reactions, including anaphylaxis. See full prescribing information for a complete list of adverse reactions.